Skip to Main content Skip to Navigation
Journal articles

Éligibilité des patients aux cellules CAR-T : avis d’experts proposé par la SFGM-TC

Abstract : The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisagenlecleucel (KymriahTM) has a marketing authorization for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia in children and young adults and of R/R diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (YescartaTM) is the treatment of DLBCL and primary R/R mediastinal B-cell lymphoma. The two products are autologous T-cells directed against CD19. This collaborative work, part of a series of expert opinion-based work, aims to give practical advice to help centers in selection of patients for commercially available CAR T-cell treatment.
Document type :
Journal articles
Complete list of metadata
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Monday, September 20, 2021 - 10:59:27 AM
Last modification on : Friday, October 22, 2021 - 2:50:03 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




David Beauvais, Emmanuel Bachy, André Baruchel, Jacques-Olivier Bay, Denis Caillot, et al.. Éligibilité des patients aux cellules CAR-T : avis d’experts proposé par la SFGM-TC. Bulletin du Cancer, John Libbey Eurotext, 2021, 108 (7-8), pp.725-729. ⟨10.1016/j.bulcan.2020.10.017⟩. ⟨inserm-03349011⟩



Record views